Market Research Logo

Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis

The 3rd edition of the report ‘Pharmaceutical and Biotechnology Construction Sector Report – UK 2016-2020 Analysis’ addresses the scale of construction activity in the pharmaceutical and biotechnology industry alongside the key contractors operating in that sector. It also assesses the health of the pharmaceutical industry and whether prospective industry performance is likely to lead to greater levels of capital and construction investment.

Key sections covered:

  • Market size and overview – value, market drivers and key issues, R&D and manufacturing activity.
  • Construction activity - in the pharmaceutical and biotechnology industries.
  • Main manufacturing and R&D facilities – the key centres of the South East, East of England, North West, North East and Scotland.
  • Construction capability - major companies involved in the pharmaceutical and biotechnology sectors including contractors, consultants and architects.
  • Funding and investment - analysis of Government resource and capital funding for science and research.
Key areas of insight include:
  • Analysis of the impact of Brexit on the UK pharmaceutical sector – there are significant issues for the industry including the regulation of medicines, EU clinical trials regulation, EU funding for research, access to R&D facilities, the single market, skills base.
  • Leading specialist supply companies to the pharmaceutical industry including: cleanroom design, construction and fit-out; clean and controlled air environments; clean air products; bio-containment and contamination control; validation and maintenance.
  • Construction costs and issues in the design of pharmaceutical R&D and manufacturing facilities including legislation, regulatory requirements, containment and environmental issues, cleanroom and laboratory design.
  • Detailed analysis of pharmaceutical clusters and centres of excellence in the UK. Many of the UK’s biotech firms are located in an area known as ‘The Golden Triangle’, with the centres of London, Cambridge, Oxford and Stevenage housing the UK’s largest biomedical cluster in the UK.
  • Review of the main challenges facing the pharmaceutical sector including slowing R&D pipelines, dwindling healthcare budgets, rising costs, impending ‘patent cliffs’, increased regulatory controls, the influence of the generic drugs market and increased pricing pressures.
Key areas covered in the report include:

MARKET OVERVIEW
  • Market definition, size and value, overview of the global pharmaceutical market, overview of the UK pharmaceutical market: biopharmaceuticals; medical technology; digital health; genomics sector.
  • Location of UK biopharmaceutical manufacturing and R&D sites.
  • Pharmaceutical/biotechnology clusters and centres of excellence: Oxfordshire biocluster; London, Cambridge and Stevenage bioclusters.
  • Regional concentration of pharmaceutical manufacturing and R&D: Northwest; East, Southeast and London; Northeast; Scotland.
  • Future of pharmaceutical manufacturing operations in the UK.
  • Value of pharmaceutical industry to the UK economy: UK trade in pharmaceuticals, sales of pharmaceutical drugs to the NHS.
  • Pharmaceutical R&D in the UK: government funding for science R&D (resource & capital funding); pharmaceutical company investment in R&D; R&D pipeline.
  • Market drivers and key issues in the pharmaceutical industry: drug patent expirations; generic drugs market; university collaboration with the pharmaceutical industry; tax implications and government legislation; long-term implications of ‘brexit’ on the UK pharmaceutical industry.
CONSTRUCTION ACTIVITY
  • Construction output in the UK pharmaceutical and biotechnology sector, forecast through to 2020, prospects for development in construction within this end use sector.
  • Construction in the industrial sector, future prospects in construction output within the sector, key influencing factors, growth in factories and warehouses.
  • Capital expenditure in the UK pharmaceutical & biotechnology sectors: R&D capital and manufacturing capital.
  • Pharmaceutical construction/development pipeline – confirmed projects to 2020.
  • Construction issues in the pharmaceutical industry – construction costs; contamination control issues; clean rooms; containment laboratories; legislation/guidelines/standards for cleanroom construction.
  • UK science parks and university innovation campuses.
  • UK Enterprise Zones and Catapult Centres.
CONSTRUCTION CAPABILITY
  • Leading specialist supply companies to the pharmaceutical industry including: cleanroom design, construction and fit-out; clean and controlled air environments; clean air products; bio-containment and contamination control; validation and maintenance.
  • Major engineering construction companies involved in the pharmaceutical and biotechnology sectors including contractors, consultants and architects - capability and project experience.
LEADING PHARMACEUTICAL COMPANIES
  • Overview and Pharmaceutical Company League Tables (Global and UK).
  • Pharmaceutical company profiles: Abbvie; AstraZeneca; Boehringer Ingelheim; GSK; Johnson & Johnson; Merck; Novartis; Pfizer; Roche; Sanofi.
  • Other smaller pharmaceutical/biotechnology companies: biotechnology/therapeutics & diagnostics; biotechnology R&D; pharmaceutical.


  • INTRODUCTION
    • Introduction
    • Sources of Information
  • SUMMARY AND MARKET PROSPECTS
    • Summary
    • UK Pharmaceuticals Sector
  • ECONOMIC ENVIRONMENT
    • GDP
      • Table GDP Data - 2013-2016 - Key Constituent Elements
    • Inflation & Interest Rates
    • Unemployment
    • Household Consumption
    • Housing & Construction
    • Sterling
      • Table Exchange Rate Fluctuations 2012-2018 - Sterling to The Dollar, And The Euro, Spot Rates
    • Population Profile
    • Conclusions
  • CONSTRUCTION ACTIVITY IN THE UK PHARMACEUTICAL AND BIOTECHNOLOGY SECTORS
    • Construction Industry
      • Overall Construction Industry
      • Non-Domestic Construction
    • Definition - Pharmaceuticals and Biotechnology
    • Market Size
      • Current Situation
      • Market Prospects
      • Construction Pipeline
        • Table UK Science and Research Projects: Forward Construction Pipeline
    • Capital Expenditure in the Pharmaceutical Sector
    • Science Parks / University Innovation Campuses
      • Table UK Science Parks - Size, Geographical Spread, Sectors and Key Partners
    • Enterprise Zones
    • Construction Issues in the Pharmaceutical Industry
      • Construction Costs
      • Contamination Control Issues
        • Table Airborne Particulate Cleanliness Classes for Cleanrooms (Based on ISO 14644-1)
  • CONSTRUCTION CAPABILITY AND SUPPLY CHAIN
    • Overview of the Supply Chain
    • Construction Consultants and Contractors
    • Specialist Cleanroom Construction, Supply and Services
  • PHARMACEUTICAL INDUSTRY MARKET SIZE AND OVERVIEW
    • Market Definition, Size and Value
      • Global Pharmaceutical Market
      • UK Pharmaceutical Market
      • Biopharmaceutical Sector
      • Medical Technology Sector
      • Digital Health Sector
      • Genomics Sector
      • Location of Biopharmaceutical Manufacturing Sites
        • Table Biopharmaceutical / Medical Technology Sectors: Major Companies and Geographical Location of Facilities in the UK - Manufacturing, R&D, And Packaging & Logistics
    • Pharmaceutical / Biotechnology Clusters
      • Oxfordshire BioCluster
      • London, Cambridge and Stevenage BioClusters
      • Regional Concentration of Pharmaceutical Manufacturing/R&D
      • Future of Pharmaceutical Manufacturing Operations in the UK
    • Value of Pharmaceutical Industry to the UK Economy
      • UK Trade in Pharmaceuticals
    • Sales of Pharmaceutical Drugs to the NHS
    • Pharmaceutical R&D in the UK
      • Government Funding for Science R&D
        • Table Government Resource Funding for Science and Research 2016-2020 by Funding Programme (£m)
        • Table Government Capital Funding for Science and Research 2016-2020 by Funding Programme (£m)
      • Pharmaceutical Company Investment in R&D
        • Table Top 25 Pharmaceutical and Biotechnology Companies by Global R&D Spend 2015 (£bn and by % of Turnover)
      • R&D Pipeline
        • Table Top 20 Global Pharmaceutical and Biotechnology Companies by Drug Pipeline Size in 2015 and 2016
    • Market Drivers and Key Issues in the Pharmaceutical Industry
      • Key General Issues Facing the Pharmaceutical Sector
      • Future of the UK Pharmaceutical Sector
  • LEADING COMPANIES IN THE PHARMACEUTICAL & BIOTECHNOLOGY SECTORS
    • Overview
    • Pharmaceutical Company League Tables
      • Global
        • Table Top 20 Global Pharmaceutical Companies by Market Share (%) 2015
      • UK
        • Table Top 10 Pharmaceutical Companies Market Share (%) 2015
    • Company Profiles
      • AbbVie
        • Table AbbVie - Key Operating and Financial Summary Data (Turnover, Capex, R&D, Principal Activities, Key UK Locations)
      • AstraZeneca
        • Table AstraZeneca - Key Operating and Financial Summary Data (Turnover, Capex, R&D, Principal Activities, Key UK Locations)
      • Boehringer Ingelheim
        • Table Boehringer Ingelheim - Key Operating and Financial Summary Data (Turnover, Capex, R&D, Principal Activities, Key UK Locations
      • GSK
        • Table GSK- Key Operating and Financial Summary Data (Turnover, Capex, R&D, Principal Activities, Key UK Locations
      • Johnson & Johnson
        • Table Johnson & Johnson - Key Operating and Financial Summary Data (Turnover, Capex, R&D, Principal Activities, Key UK Locations)
      • Merck
        • Table Merck - Key Operating and Financial Summary Data (Turnover, Capex, R&D, Principal Activities, Key UK Locations)
      • Novartis
        • Table Novartis - Key Operating and Financial Summary Data (Turnover, Capex, R&D, Principal Activities, Key UK Locations)
      • Pfizer
        • Table Pfizer- Key Operating and Financial Summary Data (Turnover, Capex, R&D, Principal Activities, Key UK Locations)
      • Roche
        • Table Roche - Key Operating and Financial Summary Data (Turnover, Capex, R&D, Principal Activities, Key UK Locations)
      • Sanofi
        • Table Sanofi - Key Operating and Financial Summary Data (Turnover, Capex, R&D, Principal Activities, Key UK Locations)
    • Other Pharmaceutical/Biotechnology Companies
      • Biotechnology - Therapeutics/Diagnostics
      • Biotechnology R&D
      • Pharmaceutical

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report